OC-29 Terlipressin and albumin vs midodrine plus octreotide and albumin in the treatment of hepatorenal syndrome in patients with cirrhosis: results of a controlled clinical trial by A.I.S.F

were treated with RFA (n=69), and the others underwent HR (n=63). The two groups were similar for liver disease status. The outcome was considered in terms of overall survival (OS) and disease-free survival (DFS) calculated by the Kaplan-Meier method. Differences among groups were validated by log-rank test. Results: The 1-, 3and 5-year OS rates for the RFA group and the HR group were 91%, 75%, 52%, and 97%, 92%, 74%, respectively. The corresponding DFS rates for the 2 groups were 64%, 28%, 5%, and 85%, 63%, 40%, respectively. OS and DFS were significantly lower in the RFA group than in the HR group (p=0.0210 and p=0.00001). The 5-year HCC recurrence rate was higher in the RFA group than in the HR group (87% vs. 60%; p = 0.0010). Conclusions: HR may provide better survival and lower recurrence rates than RFA for patients with VE HCC. HR should still be employed for those patients with a single small tumor and well-preserved liver function, as suggested by BCLC staging system. RFA should be chosen for patients with an unresectable single tumor for HCC position and grade of liver damage.